TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02115802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
Study: NCT05671731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneo Synergy 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project FUN
Description: Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
Study: NCT00807651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AHSCT
Description: All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin therapy
Description: All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
Study: NCT00226577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (AlimtaR) 500 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
Study: NCT04967326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)
Study: NCT04273308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
Study: NCT04252651

Intervention type: OTHER
Intervention: Blood Draw
Description: This study will involve blood draws to test for specific cytokines
Study: NCT03345771

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial Barrier Dressing
Description: Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT)
Description: PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
Study: NCT01075672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
Study: NCT00455572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK1572932A
Description: Intramuscular injection, 8 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK1572932A
Description: Intramuscular injection, 8 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK1572932A
Description: Intramuscular injection, 8 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK1572932A
Description: Intramuscular injection, 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Description: Four cycles with doses based on patient's body surface area, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Description: Four cycles with doses based on patient's body surface area, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Description: Four cycles with doses based on patient's body surface area, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Four cycles with doses based on patient's body surface area , intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Four cycles with doses based on patient's body surface area , intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Four cycles with doses based on patient's body surface area , intravenous administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Regimen will be based upon the site's own standard procedures
Study: NCT02917421

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: (Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: (Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
Study: NCT03833908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAF-1217
Description: Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
Study: NCT00006401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNO
Description: Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Nitrogen
Study: NCT02037009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care organization (anesthetic surveillance)
Study: NCT02408978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXP005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Study: NCT05125614

Intervention type: OTHER
Intervention: No adjuvant chemotherapy
Description: There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
Study: NCT02872584

Intervention type: DRUG
Intervention: Prednisone
Description: prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
Study: NCT02368860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, irinotecan, capecitabine
Description: fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
Study: NCT06260462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual-release hydrocortisone
Description: Oral tablets 20-25-30-40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional glucocortidois
Description: Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
Study: NCT03778021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Gardening Exposure
Description: Assistance provided with planting and maintaining the school garden

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Gardening Curriculum
Description: 14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
Study: NCT02980666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05 mg/kg/day SC injection once daily for 24 weeks.
Study: NCT01829321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0974
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Study: NCT03331302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon-129 MRI (Experimental)
Description: MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
Study: NCT00783614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325mg
Description: Patients randomized to Aspirin 325mg po daily versus placebo pill daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month
Study: NCT02497729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Written Checklist
Description: Use of a written checklist pre and peri-intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Written Checklist
Description: Use of a written checklist pre and peri-intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head of Bed Up
Description: Raising the patient's head of bed to 25 degrees

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head of Bed Up
Description: Raising the patient's head of bed to 25 degrees
Study: NCT06392334

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Biopsy of lung tissue
Study: NCT05639140

Intervention type: OTHER
Intervention: Data collection
Description: Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected

Intervention type: OTHER
Intervention: Data collection
Description: Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
Study: NCT04430504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary telerehabilitation
Description: weekly video meetings to instruct and monitor self-exercises at home
Study: NCT01671033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation
Description: Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation
Description: Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
Study: NCT03331302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive Xenon-133 scintigraphy (Active Comparator)
Description: Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
Study: NCT00902759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program.
Study: NCT04456621

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBT
Description: Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
Study: NCT01588899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU uterine fibroid treatment
Description: A single treatment session for uterine fibroids with the MR-HIFU device.
Study: NCT00627250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100 mg every morning and 12 noon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Amantadine 100 mg every morning and 12 noon
Study: NCT01359904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dialysate bath
Description: The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
Study: NCT02557191

Intervention type: OTHER
Intervention: Observational study
Study: NCT04357756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
Study: NCT00990782

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PillCam ESO Capsule Endoscope
Description: Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
Study: NCT01587716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (Inhaled) Single Dose
Description: 250, 1000 and 2000 microgram (proposed doses)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Inhaled) Single Dose
Description: Inhaled 0.9% sodium chloride solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (Inhaled) Repeat Dose
Description: 2000 microgram (proposed dose) administered 4 times a day for two consecutive days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Inhaled) Repeat Dose
Description: Inhaled 0.9% sodium cholride solution
Study: NCT00267826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
Study: NCT02340117

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
Study: NCT01400191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
Study: NCT03217916

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa assay of podocyte glycoprotein in urine
Description: Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information.

Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa assay of podocyte glycoprotein in urine
Description: Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information.
Study: NCT04004975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
Study: NCT00135811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF and Dexamethasone
Description: MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg
Study: NCT03472391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
Study: NCT00720668

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: radiofrequency ablation for HCC
Study: NCT01156974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and care guide
Description: Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education only
Description: patients receive education about care goals